ModernMedicine Resource Center More Topics

Hepatology Resource Center

Shorter hepatitis C regimen effective in black patientsMore patients could take advantage of shorter direct-acting antiviral treatment duration.
Hepatitis C virus screening remains low among baby boomersFemales, Hispanics screened less often for highly curable infection.
Hidden chronic hepatitis C infections remain hard to detectWith the advent of new direct-acting antiviral agents, HCV treatment has greatly improved, making identification of infected individuals even more imperative.
HCV screening common but follow-up lacking in young opioid usersMore effort needed to integrate screening with follow-up care to prevent spread of the virus.
HIV/HCV infected drug users an ideal population for direct-acting antiviral useThose using illicit drugs and co-infected with HIV and hepatitis C are willing to use direct-acting anti-viral agents, says a new study.
Ethnic disparities evaporate with DAA treatment of hepatitis C infectionsHispanic and Asian patients have a higher risk of cirrhosis and liver cancer, but direct-antiviral treatment eliminates ethnic disparities.
Breaking barriers to hepatitis C treatment in the DAA eraTargeted efforts may improve the reach of treatment with direct-acting antiviral agents, according to a new study.
Eight-week drug combo regimen maintains SVR in real-world settingResearchers: Treatment-naïve patients infected with genotype 1 hepatitis C virus can receive shorter regimen.
Systematic review: DAAs provide cost-effective treatment for hepatitis CTimely treatment with direct-acting antivirals is highly cost-effective in virtually all patients infected with HCV.
Underserved HCV patients benefiting from telemedicineAn innovative telemedicine model could substantially reduce the burden of chronic hepatitis C infection.